Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
November 26 2019 - 3:00PM
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading
off-the-shelf, allogeneic T-cell immunotherapy company developing
novel treatments for patients with cancer, autoimmune and viral
diseases, today announced that Pascal Touchon, the Company's
President and Chief Executive Officer, will participate in a
fireside chat at the Evercore ISI Second Annual HealthCONx
Conference on Tuesday, December 3, 2019 at 3:50 p.m. EST. The
conference will be held at the Four Seasons Hotel in Boston, MA.
A live audio webcast will be available by visiting the Investors
and Media - Events and Presentations section of atarabio.com. An
archived replay of the webcast will be available on the Company's
website for 14 days following the live webcast.
About Atara Biotherapeutics, Inc.Atara
Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf,
allogeneic T-cell immunotherapy company developing novel treatments
for patients with cancer, autoimmune and viral diseases. Atara’s
technology platform leverages research collaborations with leading
academic institutions with the Company’s scientific, clinical,
regulatory and manufacturing expertise. Atara’s pipeline includes
tab-cel® (tabelecleucel), which is in Phase 3 development for
patients with Epstein-Barr virus-associated post-transplant
lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage
development for other EBV-associated hematologic malignancies and
solid tumors, including nasopharyngeal carcinoma (NPC); T-cell
immunotherapies targeting EBV antigens believed to be important for
the potential treatment of multiple sclerosis; and next-generation
chimeric antigen receptor T-cell (CAR T) immunotherapies. The
company was founded in 2012 and is co-located in South San
Francisco and Southern California. Our Southern California hub is
anchored by the state-of-the-art Atara T-cell Operations and
Manufacturing (ATOM) facility in Thousand Oaks, California. For
additional information about the company, please visit
atarabio.com.
INVESTOR & MEDIA CONTACT:
John Craighead, Ph.D.Vice President, Investor Relations &
Corporate CommunicationsAtara
Biotherapeutics650-410-3012jcraighead@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024